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Comments on: Frequency of human platelet antigens in oncohematological patients with 
thrombocytopenia and the probability of incompatibility to platelet transfusions
Platelets share antigens with other cells such as ABH and HLA class I antigens, but also 
express specific antigens. Platelet specific antigens are identified according to a nomenclature 
devised by the International Society of Blood Transfusion and are referred to as Human 
Platelet Antigens (HPA). These include glycoproteins expressed on platelet surfaces such as 
GPIIb/IIIa, the von Willebrand factor receptor GP Ib/IX, among others. Polymorphisms in 
the genes that code for these proteins result in different HPA patterns, which can result in 
the exposure of humans to incompatible HPA during platelet transfusions or pregnancy of 
an HPA-incompatible fetus. Significant differences in the prevalence of HPA polymorphisms 
have been described in different populations and HPA polymorphism frequencies in Brazil 
have been elegantly described in different ethnic groups(1). Alloimmunization to HPA can 
result in clinically significant problems such as neonatal alloimmune thrombocytopenia and 
post-transfusion purpura. The former occurs when an alloimmunized mother gives birth 
to an HPA-incompatible newborn resulting in neonatal thrombocytopenia. The latter is an 
extremely rare condition in which the development of anti-HPA antibodies, usually anti-
HPA-1a, results in sudden (within 7-10 days after a transfusion), severe and self-limiting 
thrombocytopenia, with destruction of both autologous and allogeneic platelets. In addition 
to these two well-recognized HPA-related disorders, HPA alloimmunization is sometimes 
associated with platelet refractoriness, although the role of HPA antibodies in this context is 
less straightforward(2).
A report on the prevalence of HPA polymorphisms in a group of multitransfused patients 
from the Transfusion Outpatient Clinic of Hospital das Clinicas (FMUSP) is presented in this 
issue of the Revista Brasileira de Hematologia e Hemoterapia (RBHH)(3). The study population 
included 150 patients with aplastic anemia or oncohematological diseases submitted to platelet 
transfusions at this Institution. In addition to presenting the HPA genotypes of this population, 
the authors performed a theoretical exercise to estimate the risk of incompatible HPA 
transfusions by comparing their results with HPA genotype frequencies from a population of 
blood donors from the same Institution. No significant differences in genotype frequency were 
observed. The study did not look for the presence of anti-HPA antibodies nor the outcome of 
transfusions and the authors mostly explored the role of HPA antigens in the development of 
platelet refractoriness. 
The availability of platelet transfusions in 1959 resulted in a dramatic reduction (from 
67% to 37%) in the percentage of bleeding-related deaths in leukemic patients(4). Since this 
time, several improvements in medical support to oncohematological patients, coupled with 
improvements in the quality of platelet transfusions, further decreased the morbidity of 
thrombocytopenia in these patients. Nonetheless, poor response to platelet transfusions or 
platelet refractoriness remains one of the most dramatic challenges in the management of 
oncohematological patients. 
Platelet refractoriness can be defined as the occurrence of an unexpected increment 
in platelet count after a platelet transfusion. The frequency of this complication in 
oncohematological patients varies depending on the study; in a recent analysis of the TRAP 
(Trial to Reduce Alloimmunization to Platelets) Study, platelet refractoriness developed in 
27% of patients with acute leukemia(5). In Brazil, a single center study published in 2004 
describes an extremely high frequency, with 80% of patients developing this complication in 
the early phase of hematopoietic stem cell transplantation(6). However, in a more recent study, 
a 19% frequency of platelet refractoriness, much closer to data of several other studies, was 
demonstrated among oncohematological patients(7). 
Platelet refractoriness can be caused by several non-excluding mechanisms, normally 
divided into immune and non-immune. Non-immune causes of platelet refractoriness include 
sepsis, disseminated intravascular coagulation, splenomegaly, fever, medications, among 
others. Immune causes include alloimmunization to antigens present on platelets due to prior 
exposure during previous transfusions, transplantation or pregnancy. It is generally accepted 
that non-immune causes account for about 80% of cases of platelet refractoriness(7).
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Platelet antigens associated with alloimmunization can be 
divided in two groups: HLA and HPA. HLA antigens are believed 
to be the primary cause of immune platelet refractoriness. HLA 
class I antigens are synthesized by platelets, which also absorb 
soluble HLA antigens from plasma, resulting in a relatively higher 
number of these molecules on the platelet surface compared 
to granulocytes and red cells(8). In contrast, platelet-specific 
antibodies, found in less than 15% of cases of immune-mediated 
platelet refractoriness, are much less frequently associated with 
platelet refractoriness and some authors even argue about the 
clinical significance of this association(2). It is also important to 
note that in the context of platelet refractoriness, the mere presence 
of antibodies does not implicate in a clinically significant effect. 
In fact, 50% of patients with anti-HLA antibodies do not manifest 
platelet refractoriness(2). This observation shows that the link 
between alloimmunization and its potential clinical consequences 
are not straightforward, and that other modifiers, many still 
unknown, determine whether alloimmunization will result in a 
clinically relevant effect. Therefore, the study presented in this 
issue of RBHH(3) confirms the HPA genotype pattern described 
by others, but the implications of these results on the risk of HPA-
related disorders and, more specifically, on platelet refractoriness, 
should be evaluated with much more caution. Nonetheless, it 
should be regarded as a relevant effort to increase the knowledge 
in the field of platelet transfusions(9). 
 
References
1. Castro V, Origa AF, Annichino-Bizzacchi JM, Soares M, Menezes 
RC, Gonçalves MS, et al. Frequencies of platelet-specific alloantigen 
systems 1-5 in three distinct ethnic groups in Brazil. Eur J 
Immunogenet. 1999;26(5):355-60.
2. Hod, E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 
2008;142(3):348-60.
3. Azevedo MR, Jens E, Nukui Y, Chamone DA. Frequency of Human 
platelet antigens in oncohematological patients with thrombocytopenia 
and the probability of incompatibility to platelet transfusions. Rev 
Bras Hematol Hemoter. 2012;34(3):202-5
4. Bayer WL, Bodensteiner DC, Tilzer LL, Adams ME. Use of platelets 
and other transfusion products in patients with malignancy. Semin 
Thromb Hemost. 1992;18(4):380-91.
5. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, 
et al. Factors affecting posttransfusion platelet increments, platelet 
refractoriness, and platelet transfusion intervals in thrombocytopenic 
patients. Blood. 2005;105(10):4106-14.
6. de Paula GG, Novaretti MC, Pozzi DH, Chamone DA. Estudo da 
refratariedade plaquetária do dia 0 ao 50, em pacientes submetidos 
a transplante de medula óssea. Rev Bras Hematol Hemoter. 
2004;26(1):3-12
7. Ferreira AA, Zulli R, Soares S, Castro V, Moraes-Souza H. 
Identification of platelet refractoriness in oncohematologic patients. 
Clinics (Sao Paulo). 2011;66(1):35-40.
8. Lalezari P, Driscoll AM. Ability of thrombocytes to acquire HLA 
specificity from plasma. Blood. 1982;59(1):167-70.
9. Ferreira AA, Soares S, Castro V, Moraes-Souza H. Platelet transfusion: 
from empiricism to scientific evidence. Rev Bras Hematol Hemoter. 
2010;32(4):335-6 
xxx
